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Abstract: Primary systemic therapy (PST) is a standard treatment for patients with locally advanced breast cancer. We report one of our 
patients to demonstrate the optimal use of FDG-PET-CT in the routine clinical workup during PST, especially when clinicians face 
contradictory clinical and pathological findings, and to show the advantages of this imaging modality in the decision-making process 
about the initial treatment choice. By reviewing the literature we would also like to confirm that FDG-PET-CT is highly sensitive in the 
measurement of the  early therapeutic response and the prediction of the complete pathological remission, as early as after the first 
cycle of chemotherapy is administered.
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 Case Report
1. Introduction
Primary systemic therapy (PST) has become a stan-
dard treatment for patients with locally advanced breast 
cancer and inflammatory breast cancer. The first goal of 
PST is to assess the sensitivity of the tumor for chemo-
therapy, namely that PST is an “in vivo test” for the drug 
resistance. The treatment can be optimized, and PST 
may allow performance of breast-conserving surgery, 
with down-staging of the tumors [1-3]. There are many 
contradictions in the literature about primary systemic 
therapy, but many studies have shown that with PST 
– particularly when complete pathological remission 
(same as pathologic complete response = pCR) was 
achieved – the overall survival (OS), the disease-free 
survival (DFS) and relapse-free survival (RFS) were 
significantly longer [1,4-8].
To measure the response to the therapy is essential, 
and to clearly identify the responder and non-responder 
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patients is crucial [9]. During the morphological response 
evaluation, even by using increasingly sensitive imaging 
modalities, it was found that during cancer treatment 
the metabolic changes were earlier in onset than the 
morphological response. This has led to the era of meta-
bolic imaging – especially positron emission tomography 
(PET) – in tumor response evaluation [8]. The PET-CT 
imaging – using [18F]-fluoro-deoxy-glucose(FDG) – is 
based on the increased metabolism and glucose uptake 
of tumors. Its biggest advantage over PET alone is the 
fusion of functional and anatomical imaging – owing 
to this it can be highly sensitive in the localization of 
viable tumor tissue in the body. Moreover FDG-PET 
can identify the therapy-induced changes in tumor 
metabolism with high sensitivity. Using FDG-PET-CT it 
was already found that after 1 or 2 cycles of anticancer 
therapy (interim PET-CT imaging) the responder and 
non-responder patients could be separated effectively 
[10,11]. With the detection of the metabolic response 
in an early phase, we could acquire information on the 
effectiveness of the systemic therapy well in advance 
compared to the morphological methods.
In our country interim PET for breast cancer could 
only be performed if the tumor showed equivocal 
clinical behavior and the result of the interim PET-CT 
may lead to changes in the chemotherapy regimen to 
be administered. Otherwise only presurgical – after 4 
or 6 cycles of PST – PET-CT is used to evaluate the 
therapeutic response for neoadjuvant treatment. In our 
case study we report one of our patients to demonstrate 
that if pathological findings and clinical behavior are not 
consistent, then the interim PET-CT shall decide if the 
clinician selected the right therapy to gain pathologic 
complete response (pCR).
2. Case Report
2.1. Patient history
Our 52-year old patient had discovered a lump in her 
right breast by self-examination. One and a half years 
before her first „detection” she had participated in 
routine mammography screening with negative results. 
She was presented in our unit with 4-6 week history of a 
rapidly growing lump in her right breast. The patient had 
no history of contraceptive medication use and she has 
never been pregnant (0/0). She was postmenopausal 
due to gynecological surgery for endometriosis, which 
included hysterectomy and bilateral adnexectomy (at 
the age of 47). Following this operation she was put on 
hormone-replacement therapy due to her symptoms for 
3 months.
2.2. Tumor presentation
On physical examination, the medical oncologist pal-
pated a lesion with nearly 4 cm in diameter in the right 
breast, at the border of the upper-outer quadrant. The 
skin of the breast showed mild signs of inflammation. 
Unfortunately, the patient did not consent to photo docu-
mentation of the symptoms.
During diagnostic imaging workup, the mammog-
raphy detected a spiculated lesion with 2.5 cm longest 
diameter in the upper-outer quadrant. The breast 
ultrasound revealed a 27x20 mm hypoechogenic non-
homogeneous mass in the upper outer quadrant of the 
right breast along with an enlarged lymph node in the 
axilla. Ultrasound guided fine needle aspiration biopsy 
(FNAB) was performed from the breast lesion. The result 
showed unequivocal malignancy with invasive grade 3 
breast cancer cells (C5).
2.3. Treatment planning
The multidisciplinary team of our department decided to 
administer PST because of the rapid growth of the tumor 
and its mastitis-like behavior. Before initiating treatment, 
ultrasound guided histological sampling (core-biopsy) 
was taken and PET-CT staging was performed.
The core-biopsy indicated nuclear grade 3 invasive 
ductal carcinoma with moderate mitotic activity (9 mito-
ses/ 10 high power fields). The immuno-histochemistry 
test provided the following results:
• estrogen, progesterone receptors and HER2: 
negative;
• Ki-67 proliferation marker: 10 % , p53 tumor sup-
pressor expression: 100% ;
• E-cadherin: positive, CK-7: positive, CK 5/6 negative.
Based on these results the cancer was classified as 
a high grade invasive ductal carcinoma (IDC) with triple-
negative characteristics. Interestingly the proliferation 
index was rather low despite the rapid growth of the 
tumor according to the clinical history.
2.4. FDG-PET-CT staging
The PET scan was performed using GE DiscoveryTM ST 
8 PET-CT device (GE Medical Systems). Standardized 
Uptake Values (SUV) were calculated and morphologi-
cal data were measured on staging PET-CT images for 
the primary tumor and axillary lymph node region. To 
measure the therapeutic response the maximum value 
of SUV was calculated (SUVmax) in each region (Table 1).
In the upper-outer quadrant of the right breast FDG-
PET-CT showed a metabolically active tumor; also the 
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skin showed mild metabolic activity in the region of the 
clinical symptoms, i.e. the erythema. Furthermore, a 
metastatic lymph node with pathologic FDG-uptake in 
the right axillary region was detected. There was no sign 
of distant metastasis, therefore clinical TNM stage was 
established as cT2cN1M0.
2.5. Primary systemic therapy
The multidisciplinary team decided to administer PST. 
The patient received 6 cycles of taxane-platina based 
PST (docetaxel-carboplatin). After the first administered 
cycle of the PST, the erythema and the mastitis-like 
symptoms were resolved almost completely, while the 
palpable lesion did not shrink significantly. The treating 
physician decided to order an interim PET-CT, to find out 
whether the metabolism of the tumor decreased in line 
with the symptoms of the skin.
The interim PET-CT scan revealed metabolic remis-
sion, which was more obvious than the morphological 
one. In the axillary lymph node region the metabolism 
also decreased markedly, and the morphological re-
sponse was better than that in the primary tumor region, 
according to RECIST 1.1 [12] complete morphological 
remission was detected (Table 1).
At the end of the sixth cycle, before the surgery, a 
restaging PET-CT was performed. There was no sign 
of metabolic activity in the primary tumor, in contrast 
to the morphological change that is the total shrinkage 
reached only 27.5 percent reduction in the longest diam-
eter of the primary tumor, which meant – according to 
RECIST 1.1 – a stable disease. The metabolically active 
axillary lymph node showed moderate uptake on the 
restaging PET-CT and its size did not reduce any further 
in the short axis diameter since the interim PET-CT scan 
(Table 1).
Table 1. FDG-PET-CT results
PET-CT scans Primary Tumor SUV Primary Tumor Size Axilla SUV Axilla Size
Staging PET 15,7 32x40 17,7 17x22
Interim PET 5,3 24x30 4,0 10x16
Restaging PET 1,7 19x29 2,5 10x12
Interim
response
∆SUV=10,4 
66,3%
25% 
RECIST: SD
∆SUV=13,7 
77,4%
41% 
RECIST: CR
Overall response
∆SUV=14  
89,2%
27,5% 
RECIST: SD
∆SUV=15,2 
85,88%
41% 
RECIST: CR
[SUV: Standardized Uptake Value; RECIST: Response Evaluation Criteria In Solid Tumors 
(version used: 1.1), SD: stable disease, CR: complete remission
Figure 1A Figure 1B Figure 1C
Figure 1 A-C. Staging (Fig.1A), interim (Fig.1B) and restaging (Fig.1C) FDG-PET-CT investigations; MIP (Maximum Intensity Projection) PET 
images. On the staging image (Fig.1C) the metabolically active tumor in the right breast and one metastatic lymph node were 
visible (arrow). The interim images (after C01) showed metabolic regression in both regions (Fig.1B), and on the restaging 
scans (after C06) the primary tumor showed metabolic complete remission, with slight residual uptake in the axillary region 
(Fig. 1C).
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2.6. Surgery and adjuvant therapy
In the surgical department, breast conserving surgery 
(sector excision) with axillary block dissection was per-
formed. The final histological examination of the surgical 
specimen provided the following results:
• The sample of the sector excision showed pathologic 
complete response in the breast, that is there was no 
sign of viable tumor cells in the specimen; just necrotic 
and fibrotic breast tissue was found (pCR).
• In the axillary block specimen – which contained 10 
lymph nodes – two nodes were infiltrated by tumor cells. 
The immuno-histochemistry resulted in a triple nega-
tive IDC with 80% of Ki-67 labeling index and 100% of 
p53 staining.
• The pathological response rate was established as 
Sataloff T-A, N-D.
In conclusion, according to the pathological staging, 
the patient was in ypT0ypN1a (2/10) TNM stage, and – 
according to the PET-CT scan performed before surgery 
– clinically free of distant metastases.
After surgery the patient received adjuvant chemo-
therapy because of the high proliferation rate detected 
in the axillary lymph node metastases, followed by 
radiation therapy (50-50/2 Gray for the right breast- and 
axillary-region).
At the time of composition of this paper the patient 
had been in complete remission. The last treatment was 
administered almost 2 years ago; 32 months elapsed 
since the diagnosis was made.
3. Discussion
FDG-PET-CT is able to measure changes in glucose 
metabolism induced by the therapy in the tumor tissue 
with high precision. This makes it a distinguished tool for 
monitoring therapy [13]. Most of the authors found an 
excellent correlation between the tumors’s FDG-uptake 
and the response of the tumor after the first cycle of che-
motherapy. In the paper of Wahl et al. [14], the reduction 
in FDG-uptake during the evaluation of the therapeutic 
response with PET-CT after the first cycle of PST (on 
the 8th day from the beginning of the therapy) was 
predictive for complete pathological remission. Lee et 
al. described (summarizing 9 different studies) that after 
the first or second cycle of chemotherapy, early assess-
ment of response with FDG-PET was predictive for the 
final pathological response [15]. Wang et al. revealed 
in their meta-analysis (16 studies) that 55-65% cut off 
reduction of the SUV after the 1st or 2nd cycle has the 
best correlation with pathological response [16]. In the 
following table (Table 2) we give a summary of those 
studies that used PET-CT after the first cycle of PST 
and defined cut-off values for the prediction of the pCR.
Rousseau et al. analyzed the sensitivity, the speci-
ficity and the negative predictive value of FDG-PET-CT 
with 40% decrease in the SUV as the threshold for 
response. The sensitivity, the specificity and the nega-
tive predictive values were 61%, 96% and 68% after the 
first cycle, 89-95-85 % after the second cycle and 88-
73-83% after third cycle for the pathological response, 
respectively [17]. In summary, they suggested that the 
best time for the assessment of the metabolic response 
is after the second cycle of the neoadjuvant therapy. 
Groheux et al. – through analyzing 9 studies – sug-
gested the same optimal timing for the interim PET-CT 
[23]. Berriolo-Riedinger et al. established in their study 
[18] – response evaluation in 47 patients after the first 
cycle – that, when using 60% ∆SUV cut-off values, the 
FDG-PET-CTs were highly predictive for the pathologic 
complete response (pCR). Schwarz-Dose et al. came to 
the conclusion that, after the first and the second course, 
Table 2. Studies evaluating the metabolic response with FDG-PET-CT after the first cycle of PST.
Study Timing of interim PET PET criteria*
Schelling et al.[10] after 1st, 2nd cycle -55% (after 2nd cycle)
Smith et al. [11] after 1st, 2nd, 5th cycle  
dynamic PET-CT performed
DUR** >20% (after 1st cycle)
Rousseau et al.[17] after 1st, 2nd, 3rd course -40% (after 2nd cycle)
Berriolo-Riedinger et al.[18] after 1st cycle -60% (after 1st cycle)
Ueda et al.[19] after 1st cycle -40% after 1st cycle
Schwarz-Dose et al.[20] after 1st and 2nd cycle -45% after 1st cycle
-55% after 2nd cycle
Keam et al.[21] after 1st cycle -50% after 1st cycle
Kolesnikov-Gauthier et al.[22] after 1st cycle decrease less than 15% is predictive for therapy failure
*decrease in the percent of the baseline (pretherapy) SUVmax
**DUR=dose uptake ratio (Patlak analysis, FDG-uptake calculated by voxels on the dynamic and static scans in Smith et al. study)
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PET performed equally. [20]. Kolesnikov-Gauthier et al. 
revealed, that less than 15% decrease in the SUV after 
the first cycle of the chemotherapy is highly predictive 
for therapy failure [22]. In the case of our patient we 
found more than 60% decrease in the SUV, and later 
the histology confirmed the pCR, so the interim PET-CT 
results were predictive of the pathological remission.
The FDG-uptake depends on several biological 
properties of the tumors. The highest level of correlation 
was found with the glucose metabolism of the cell (e.g. 
GLUT-1 expression) and with the Ki-67 proliferation 
marker [24,25]. It is well documented that using Ki-67 
labeling index (LI) the response to therapy is predict-
able – the high number of mitotic cells suggests good 
response for cytotoxic treatment. Furthermore Ki-67 LI 
plays an important role in the prognostic assessment of 
the tumor as well [26-28]. The correlation between Ki-67 
LI and the FDG-uptake of the tumor is a frequently ex-
amined question. Buck et al. showed that low prolifera-
tion activity was associated with low FDG-uptake, and 
inversely, high Ki-67 expression was associated with 
high FDG-avidity [25]. Buck [24], Avril [29], and Bos [30] 
confirmed that in invasive ductal carcinomas the Ki-67 
LI is higher than in the lobular type tumors. Shimoda 
et al. [31], Gil-Rendo et al. [32] and Koolen et al. [33] 
found significant correlation between Ki-67 LI and the 
SUVmax, as well as between the mitotic count and the 
FDG-uptake. Tchou et al. reported that triple negative 
breast cancer displays higher Ki-67 expression, grade 
and mitotic count than other histological subtypes and 
their FDG-uptake is also significantly higher [34].
In our case we found apparently conflicting results. 
The core-biopsy showed low Ki-67 LI, although the other 
pathological properties suggested aggressive biological 
behavior of the tumor and the mitotic activity was also 
moderate. The aggressive behavior and the relatively 
low proliferation index suggested different chances 
of the outcome to the neoadjuvant treatment. On the 
contrary, in the surgical specimen of the involved axil-
lary lymph nodes the Ki-67 index was high (80%) and 
complete pathological remission was observed in the 
primary tumor – that maybe suggests high proliferation 
rate before the therapy.
The possible causes of these contradictions are 
as follows: the measurement of Ki-67 LI is cheap and 
easy to perform in every pathological department, but 
it has shortfalls related to the subjective judgment of 
the pathologist, the intra- and inter-observer variability 
(especially in Grade 2 carcinomas), and the differences 
between the applied antibodies [28,35]. Furthermore, in-
tra-tumor variations of MIB-1 scoring were also reported 
in the assessment of individual cancers by Iqbal et al 
[36], which suggest that the place of the sampling and 
the number of the specimens are important factors in 
case of core-biopsies as well. But in the measurement 
of the cell proliferation, the Ki-67 expression is the only 
validated and trusted marker nowadays in spite of its 
disadvantages in the therapeutic decision for breast 
cancer management [37].
By knowing these limitations of the immuno-
histochemistry, our multidisciplinary team decided to 
administer PST, based on the clinical data, the mastitis-
like symptoms, the rapidly growing lesion and the high 
metabolic activity of the tumor, with strict monitoring 
of the tumor response, because of the relatively low 
Ki-67 LI in the core-biopsy. After considering the results 
of the interim and pre-surgical PET-CT scans and the 
pathological examination of the surgical specimen, we 
suspect that the core-biopsy sampling was not fully 
representative for some of the biological properties of 
the tumor (although the different proliferation rate in 
the axillary region could be caused by changes in the 
biological behavior during the metastatic spreading in 
the lymphoid system, as well). This is the underlying 
advantage of FDG-PET-CT: it maps the whole tumor, 
not just a representative part of the lesion. Moreover 
the whole-body scan also gives information about the 
locoregional and distant spread of the tumor.
4. Conclusions
The FDG-PET-CT is highly recommended for staging 
and it has clear advantages in therapy monitoring. 
Metabolic changes detected by FDG-PET are sensitive 
markers for therapeutic response, especially in predict-
ing the pathological remission. This case was really 
instructive for the indication during the PST: if some of 
the core-biopsy results and the clinical behavior are not 
consistent, the FDG-PET-CT results could aid in clinical 
decision-making. With the routine use of interim imaging 
techniques during neoadjuvant therapy, the ineffective 
treatments could safely be modified and the effective 
therapy could be prolonged or enhanced in an earlier 
phase of the treatment. This new perspective in the 
management of primary systemic therapy might offer 
an early opportunity for individualized cancer treatment, 
which is our main goal in daily practice.
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